Skip to main content

Table 1 Characteristic of participants with ME/CFS (n = 174)—overall functioning and symptom status at intake

From: Natural killer cytotoxicity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a multi-site clinical assessment of ME/CFS (MCAM) sub-study

 

Mean

Std. Dev.

Std. error

Min.

Lower quartile

Median

Upper quartile

Max.

SF-36 (0–100)

Physical function

41.21

23.42

1.78

0.00

25.00

40.00

55.00

100.00

Role physical

16.13

28.95

2.21

0.00

0.00

0.00

25.00

100.00

Bodily pain

42.19

23.56

1.79

0.00

22.00

41.00

51.00

100.00

Vitality

19.77

16.92

1.29

0.00

5.00

15.00

30.00

80.00

General health

27.20

17.14

1.30

0.00

15.00

25.00

35.00

77.00

Role emotional

85.96

31.69

2.42

0.00

100.00

100.00

100.00

100.00

Social function

27.17

23.32

1.77

0.00

0.00

25.00

37.50

100.00

Mental health

68.02

18.93

1.44

16.00

56.00

72.00

84.00

96.00

MFI-20 (0–20)

General fatigue

17.95

2.46

0.19

9.00

17.00

19.00

20.00

20.00

Physical fatigue

17.31

2.69

0.20

6.00

16.00

18.00

20.00

20.00

Reduced activity

15.77

3.56

0.27

5.00

14.00

16.00

19.00

20.00

Reduced motivation

11.62

3.83

0.29

4.00

9.00

12.00

14.00

20.00

Mental fatigue

14.37

3.70

0.28

4.00

12.00

15.00

17.00

20.00

CDC-SI

Fatigue duration (yrs)

13.62

10.42

0.80

0.25

5.00

12.00

21.00

61.00

Number of CFS symptoms

5.76

2.02

0.16

0.00

5.00

6.00

7.00

8.00

CFS symptom score

50.99

24.01

1.87

0.00

36.25

51.50

66.50

115.50

PROMIS (T-score)

Sleep disturbance

58.45

7.86

0.60

38.00

54.30

58.30

63.70

76.50

Sleep Related impairment

60.73

8.22

0.62

30.00

56.10

61.30

66.30

80.00

Pain intensity

59.56

9.09

0.69

41.00

56.10

60.90

65.50

78.30

Pain behavior

56.01

7.88

0.61

36.70

54.80

58.60

60.60

68.30